Stock Analysis on Net
Stock Analysis on Net

Moderna Inc. (NASDAQ:MRNA)

This company has been moved to the archive! The financial data has not been updated since November 7, 2024.

Analysis of Short-term (Operating) Activity Ratios

Microsoft Excel

Short-term Activity Ratios (Summary)

Turnover Ratios

Average No. Days

Moderna Inc., short-term (operating) activity ratios

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Turnover Ratios
Inventory turnover 23.23 5.71 1.82 0.17 —
Receivables turnover 7.48 13.31 5.57 0.14 0.00
Payables turnover 9.03 11.12 8.67 0.43 0.00
Working capital turnover 0.91 2.17 2.55 0.10 0.00
Average No. Days
Average inventory processing period 16 64 201 2,141 —
Add: Average receivable collection period 49 27 66 2,539 —
Operating cycle 65 91 267 4,680 —
Less: Average payables payment period 40 33 42 845 —
Cash conversion cycle 25 58 225 3,835 —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).


The operational activity ratios indicate a profound transformation in efficiency and asset management from 2020 through 2023. The company transitioned from a state of extreme operational latency to a highly streamlined model characterized by rapid asset turnover and a significantly compressed cash cycle.

Inventory Management Efficiency
A massive acceleration in inventory movement is evident, with the inventory turnover ratio rising consistently from 0.17 in 2020 to 23.23 in 2023. This is mirrored by the average inventory processing period, which collapsed from an unsustainable 2,141 days in 2020 to only 16 days by the end of 2023, suggesting a highly optimized supply chain and production output.
Receivables and Payables Dynamics
Receivables turnover saw a sharp increase from 0.14 in 2020 to a peak of 13.31 in 2022, before moderating to 7.48 in 2023. Consequently, the average receivable collection period dropped from 2,539 days in 2020 to 27 days in 2022, though it lengthened slightly to 49 days in 2023. Payables turnover remained relatively stable after an initial jump in 2021, with the payment period settling between 33 and 42 days from 2021 to 2023.
Operating and Cash Conversion Cycles
The operating cycle experienced a drastic reduction, falling from 4,680 days in 2020 to 65 days in 2023. This efficiency gain is further reflected in the cash conversion cycle, which declined from 3,835 days in 2020 to 25 days in 2023. This trend demonstrates a significant improvement in the speed at which cash is recovered from investments in operating assets.
Working Capital Utilization
Working capital turnover peaked at 2.55 in 2020 and exhibited a downward trend thereafter, reaching 0.91 in 2023. This decline suggests that the growth in working capital has outpaced the growth in sales, or that the company is maintaining a larger liquidity buffer relative to its current revenue generation.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Inventory Turnover

Moderna Inc., inventory turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Cost of sales 4,693 5,416 2,617 8 —
Inventory 202 949 1,441 47 —
Short-term Activity Ratio
Inventory turnover1 23.23 5.71 1.82 0.17 —
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 4.98 4.87 5.58 — —
Amgen Inc. 0.89 1.30 1.58 — —
Bristol-Myers Squibb Co. 4.02 4.33 4.74 — —
Danaher Corp. 3.80 4.03 4.16 — —
Eli Lilly & Co. 1.23 1.54 1.88 — —
Gilead Sciences Inc. 3.64 3.75 4.08 — —
Johnson & Johnson 2.37 2.49 2.87 — —
Merck & Co. Inc. 2.54 2.95 2.29 — —
Pfizer Inc. 2.45 3.82 3.40 — —
Regeneron Pharmaceuticals Inc. 0.70 0.65 1.25 — —
Thermo Fisher Scientific Inc. 5.06 4.60 3.88 — —
Vertex Pharmaceuticals Inc. 1.71 2.35 2.56 — —
Inventory Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 2.55 3.06 3.11 — —
Inventory Turnover, Industry
Health Care 7.36 7.85 7.90 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Inventory turnover = Cost of sales ÷ Inventory
= 4,693 ÷ 202 = 23.23

2 Click competitor name to see calculations.


The operational data reveals a significant acceleration in inventory efficiency between 2020 and 2023. A consistent and sharp upward trajectory in the inventory turnover ratio indicates a transition toward a lean inventory management model, characterized by a rapid increase in the velocity of stock movement relative to the cost of sales.

Cost of Sales Trends
A massive expansion in the cost of sales is observed from 2020 to 2022, rising from 8 million USD to a peak of 5,416 million USD. In 2023, this figure experienced a slight contraction to 4,693 million USD, though it remained several orders of magnitude higher than the 2020 baseline.
Inventory Volume Dynamics
Inventory levels peaked in 2021 at 1,441 million USD. Following this peak, a substantial downward trend occurred, with inventory decreasing to 949 million USD in 2022 and further plummeting to 202 million USD by December 31, 2023. This represents a sharp reduction in capital tied up in physical stock.
Inventory Turnover Interpretation
The inventory turnover ratio rose exponentially from 0.17 in 2020 to 23.23 in 2023. This increase is the result of the divergence between high cost of sales and aggressively reduced inventory levels. The data indicates that the organization shifted from a phase of heavy accumulation to a phase of high utilization, drastically reducing the average time inventory is held before being sold.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Receivables Turnover

Moderna Inc., receivables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Net product sales 6,671 18,435 17,675 200 —
Accounts receivable, net 892 1,385 3,175 1,391 5
Short-term Activity Ratio
Receivables turnover1 7.48 13.31 5.57 0.14 0.00
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 4.87 5.16 5.63 — —
Amgen Inc. 3.70 4.46 4.96 — —
Bristol-Myers Squibb Co. 4.93 5.48 5.65 — —
Danaher Corp. 6.09 6.40 6.36 — —
Eli Lilly & Co. 3.75 4.14 4.24 — —
Gilead Sciences Inc. 5.78 5.65 6.01 — —
Johnson & Johnson 5.73 5.88 6.14 — —
Merck & Co. Inc. 5.81 6.27 5.28 — —
Pfizer Inc. 5.33 9.24 7.16 — —
Regeneron Pharmaceuticals Inc. 2.31 2.28 2.66 — —
Thermo Fisher Scientific Inc. 5.21 5.53 4.92 — —
Vertex Pharmaceuticals Inc. 6.31 6.19 6.66 — —
Receivables Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 4.96 5.76 5.54 — —
Receivables Turnover, Industry
Health Care 7.66 8.22 8.00 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Receivables turnover = Net product sales ÷ Accounts receivable, net
= 6,671 ÷ 892 = 7.48

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals significant volatility in the efficiency of receivables management between 2020 and 2023. The company experienced an initial phase of low collection efficiency followed by a period of rapid optimization, ending with a moderate decline as sales volumes contracted.

Net Product Sales Trends
A massive expansion in revenue occurred between 2020 and 2022, with sales increasing from 200 million to a peak of 18.4 billion. This growth trajectory reversed in 2023, with net product sales declining to 6.7 billion.
Accounts Receivable Dynamics
Net accounts receivable grew sharply in 2020 and 2021, peaking at 3.2 billion. Subsequently, a consistent downward trend was observed, with receivables decreasing to 1.4 billion in 2022 and further to 892 million by the end of 2023.
Receivables Turnover Efficiency
The receivables turnover ratio demonstrates a dramatic shift in operational efficiency. An initial ratio of 0.14 in 2020 indicates an extremely slow conversion of receivables into cash. This improved substantially to 5.57 in 2021 and reached a peak of 13.31 in 2022, suggesting highly optimized collection processes during the peak sales period. In 2023, the ratio declined to 7.48, reflecting a slowdown in turnover that corresponds with the overall reduction in sales volume.

The correlation between peaking sales and the peaking turnover ratio in 2022 suggests that the company successfully scaled its credit and collection infrastructure to match its commercial growth. However, the subsequent decline in 2023 indicates that while receivables are lower in absolute terms, they are not being cleared as rapidly relative to the current lower volume of sales.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Payables Turnover

Moderna Inc., payables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Cost of sales 4,693 5,416 2,617 8 —
Accounts payable 520 487 302 18 7
Short-term Activity Ratio
Payables turnover1 9.03 11.12 8.67 0.43 0.00
Benchmarks
Payables Turnover, Competitors2
AbbVie Inc. 5.54 5.94 6.05 — —
Amgen Inc. 5.32 4.08 4.72 — —
Bristol-Myers Squibb Co. 3.28 3.33 3.37 — —
Danaher Corp. 5.58 5.45 4.48 — —
Eli Lilly & Co. 2.73 3.43 4.38 — —
Gilead Sciences Inc. 11.81 6.25 9.36 — —
Johnson & Johnson 2.76 2.66 2.70 — —
Merck & Co. Inc. 4.11 4.08 2.96 — —
Pfizer Inc. 3.72 5.04 5.53 — —
Regeneron Pharmaceuticals Inc. 2.99 2.65 4.32 — —
Thermo Fisher Scientific Inc. 8.97 7.67 6.83 — —
Vertex Pharmaceuticals Inc. 3.46 3.55 4.64 — —
Payables Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 4.25 4.28 4.23 — —
Payables Turnover, Industry
Health Care 5.97 5.79 5.84 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Payables turnover = Cost of sales ÷ Accounts payable
= 4,693 ÷ 520 = 9.03

2 Click competitor name to see calculations.


Operational activity reflects a period of exponential growth between 2020 and 2022, followed by a phase of stabilization in 2023. The cost of sales increased drastically from 8 million USD in 2020 to a peak of 5,416 million USD in 2022, before moderating to 4,693 million USD in 2023. During the same period, accounts payable exhibited a consistent upward trajectory, rising from 7 million USD in 2019 to 520 million USD by the end of 2023.

Payables Turnover Trends
A significant acceleration in the payables turnover ratio occurred between 2020 and 2022, moving from 0.43 to a peak of 11.12. This rapid increase indicates a substantial rise in the frequency of supplier payments as the scale of operations expanded. In 2023, the ratio declined to 9.03, reflecting a reduction in the velocity of payable settlements.
Analysis of Operational Efficiency and Obligations
The 2023 fiscal year shows a divergence between procurement costs and outstanding obligations. While the cost of sales decreased from 5,416 million USD to 4,693 million USD, accounts payable continued to grow, reaching 520 million USD. This combination resulted in the observed decline in the turnover ratio, suggesting a shift toward longer payment terms or an increase in the average balance owed to suppliers relative to the volume of goods and services consumed.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Working Capital Turnover

Moderna Inc., working capital turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Current assets 10,325 13,431 16,071 6,298 1,129
Less: Current liabilities 3,015 4,923 9,128 4,389 143
Working capital 7,310 8,508 6,943 1,909 986
 
Net product sales 6,671 18,435 17,675 200 —
Short-term Activity Ratio
Working capital turnover1 0.91 2.17 2.55 0.10 0.00
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. 2.25 3.82 3.37 — —
Bristol-Myers Squibb Co. 4.60 8.30 3.95 — —
Danaher Corp. 4.22 4.20 8.40 — —
Eli Lilly & Co. — 31.84 8.33 — —
Gilead Sciences Inc. 5.61 8.42 8.54 — —
Johnson & Johnson 11.81 — 5.95 — —
Merck & Co. Inc. 9.29 5.16 7.62 — —
Pfizer Inc. — 11.09 4.83 — —
Regeneron Pharmaceuticals Inc. 0.82 0.96 1.59 — —
Thermo Fisher Scientific Inc. 4.05 5.46 5.87 — —
Vertex Pharmaceuticals Inc. 0.93 0.85 1.02 — —
Working Capital Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 6.68 7.25 5.87 — —
Working Capital Turnover, Industry
Health Care 10.99 11.30 8.57 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Working capital turnover = Net product sales ÷ Working capital
= 6,671 ÷ 7,310 = 0.91

2 Click competitor name to see calculations.


The analysis of operating activity between 2019 and 2023 reveals a period of extreme volatility in resource utilization and revenue generation. Working capital experienced a consistent upward trajectory from 2019, increasing from US$ 986 million to a peak of US$ 8,508 million in 2022, before contracting to US$ 7,310 million in 2023. This expansion of liquid assets occurred alongside a dramatic fluctuation in net product sales, which peaked in 2022 before experiencing a significant decline.

Net Product Sales Trends
A massive acceleration in commercial activity is observed between 2020 and 2021, with sales rising from US$ 200 million to US$ 17,675 million. This growth peaked in 2022 at US$ 18,435 million, followed by a sharp contraction in 2023, where sales fell to US$ 6,671 million, representing a decrease of approximately 63.8% from the previous year.
Working Capital Turnover Performance
The working capital turnover ratio mirrors the volatility of product sales. An initial ratio of 0.10 in 2020 surged to 2.55 in 2021, indicating a highly efficient conversion of working capital into sales during the initial commercial scaling phase. However, a downward trend followed, with the ratio declining to 2.17 in 2022 and dropping further to 0.91 in 2023.
Efficiency and Resource Utilization
The decline in the turnover ratio to 0.91 by the end of 2023 suggests a diminishing capacity to generate sales relative to the capital invested in current assets and liabilities. While working capital was reduced by approximately 14% in 2023, the far more aggressive decline in net product sales resulted in a significant reduction in operational efficiency, bringing the turnover ratio below the 1.0 threshold.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Average Inventory Processing Period

Moderna Inc., average inventory processing period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data
Inventory turnover 23.23 5.71 1.82 0.17 —
Short-term Activity Ratio (no. days)
Average inventory processing period1 16 64 201 2,141 —
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 73 75 65 — —
Amgen Inc. 411 281 231 — —
Bristol-Myers Squibb Co. 91 84 77 — —
Danaher Corp. 96 91 88 — —
Eli Lilly & Co. 298 237 194 — —
Gilead Sciences Inc. 100 97 89 — —
Johnson & Johnson 154 147 127 — —
Merck & Co. Inc. 144 124 159 — —
Pfizer Inc. 149 95 107 — —
Regeneron Pharmaceuticals Inc. 519 562 292 — —
Thermo Fisher Scientific Inc. 72 79 94 — —
Vertex Pharmaceuticals Inc. 214 156 143 — —
Average Inventory Processing Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences 143 119 117 — —
Average Inventory Processing Period, Industry
Health Care 50 46 46 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 23.23 = 16

2 Click competitor name to see calculations.


The financial metrics reveal a substantial improvement in inventory management efficiency between 2020 and 2023, characterized by a rapid acceleration in inventory turnover and a corresponding drastic reduction in the average processing period.

Inventory Turnover
A consistent and sharp upward trend is observed in the inventory turnover ratio. Starting from a low of 0.17 in 2020, the ratio increased to 1.82 in 2021, 5.71 in 2022, and reached 23.23 by the end of 2023. This trajectory indicates a significant increase in the frequency with which inventory is sold and replaced over the reporting period.
Average Inventory Processing Period
The average inventory processing period exhibited a mirrored downward trend, decreasing from an exceptionally high 2,141 days in 2020 to 201 days in 2021, 64 days in 2022, and finally 16 days in 2023. This decline represents a transition from prolonged inventory holding times to a highly streamlined distribution cycle.

The inverse correlation between these two metrics confirms a transition toward operational maturity. The reduction of the processing period to 16 days by 2023 suggests that the supply chain and demand fulfillment processes have been optimized, resulting in significantly higher liquidity of current assets and reduced capital tied up in unsold stock.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Average Receivable Collection Period

Moderna Inc., average receivable collection period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data
Receivables turnover 7.48 13.31 5.57 0.14 0.00
Short-term Activity Ratio (no. days)
Average receivable collection period1 49 27 66 2,539 —
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 75 71 65 — —
Amgen Inc. 99 82 74 — —
Bristol-Myers Squibb Co. 74 67 65 — —
Danaher Corp. 60 57 57 — —
Eli Lilly & Co. 97 88 86 — —
Gilead Sciences Inc. 63 65 61 — —
Johnson & Johnson 64 62 59 — —
Merck & Co. Inc. 63 58 69 — —
Pfizer Inc. 69 40 51 — —
Regeneron Pharmaceuticals Inc. 158 160 137 — —
Thermo Fisher Scientific Inc. 70 66 74 — —
Vertex Pharmaceuticals Inc. 58 59 55 — —
Average Receivable Collection Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences 74 63 66 — —
Average Receivable Collection Period, Industry
Health Care 48 44 46 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 7.48 = 49

2 Click competitor name to see calculations.


An analysis of short-term operating activity reveals a period of extreme volatility followed by a transition toward stabilization in credit collection efficiency between 2020 and 2023.

Receivables Turnover
A significant upward trajectory is observed from 2020 to 2022, with the turnover ratio increasing from 0.14 to a peak of 13.31. This rapid acceleration indicates a substantial improvement in the efficiency of converting receivables into cash. However, this trend reversed in 2023, as the ratio declined to 7.48, suggesting a reduction in the velocity of credit recovery during the most recent fiscal year.
Average Receivable Collection Period
The collection period experienced a drastic contraction, falling from 2,539 days in 2020 to 66 days in 2021. This efficiency peaked in 2022, when the period reached a minimum of 27 days. In 2023, the collection period extended to 49 days, marking a moderate increase in the time required to collect outstanding payments, though the figure remains significantly lower than the levels recorded in 2020 and 2021.

The correlation between the turnover ratio and the collection period confirms a shift from an initial phase of negligible collection activity to a highly efficient operational state, followed by a recent moderate expansion of the credit cycle.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Operating Cycle

Moderna Inc., operating cycle calculation, comparison to benchmarks

No. days

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data
Average inventory processing period 16 64 201 2,141 —
Average receivable collection period 49 27 66 2,539 —
Short-term Activity Ratio
Operating cycle1 65 91 267 4,680 —
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. 148 146 130 — —
Amgen Inc. 510 363 305 — —
Bristol-Myers Squibb Co. 165 151 142 — —
Danaher Corp. 156 148 145 — —
Eli Lilly & Co. 395 325 280 — —
Gilead Sciences Inc. 163 162 150 — —
Johnson & Johnson 218 209 186 — —
Merck & Co. Inc. 207 182 228 — —
Pfizer Inc. 218 135 158 — —
Regeneron Pharmaceuticals Inc. 677 722 429 — —
Thermo Fisher Scientific Inc. 142 145 168 — —
Vertex Pharmaceuticals Inc. 272 215 198 — —
Operating Cycle, Sector
Pharmaceuticals, Biotechnology & Life Sciences 217 182 183 — —
Operating Cycle, Industry
Health Care 98 90 92 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 16 + 49 = 65

2 Click competitor name to see calculations.


The operating cycle experienced a drastic contraction between 2020 and 2023, indicating a significant acceleration in the ability to convert current assets into cash. This trend is characterized by a shift from anomalous, high-duration periods in 2020 to a streamlined operational model by the end of 2023, resulting in a substantial improvement in overall liquidity and working capital efficiency.

Average Inventory Processing Period
A sharp downward trend is observed, with the period decreasing from 2,141 days in 2020 to 16 days in 2023. This precipitous decline suggests a fundamental shift in inventory management and supply chain velocity, moving from extreme stagnation to a highly efficient turnover rate.
Average Receivable Collection Period
The collection period declined dramatically from 2,539 days in 2020 to a low of 27 days in 2022. While a modest increase to 49 days occurred in 2023, the metric remains significantly lower than the 2020 baseline, reflecting a more effective process for converting credit sales into cash.
Operating Cycle
The total operating cycle was reduced from 4,680 days in 2020 to 65 days in 2023. This compression is the direct result of the combined reductions in both inventory processing and receivable collection times, signifying a vastly optimized cash-to-cash cycle.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Average Payables Payment Period

Moderna Inc., average payables payment period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data
Payables turnover 9.03 11.12 8.67 0.43 0.00
Short-term Activity Ratio (no. days)
Average payables payment period1 40 33 42 845 —
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
AbbVie Inc. 66 61 60 — —
Amgen Inc. 69 90 77 — —
Bristol-Myers Squibb Co. 111 109 108 — —
Danaher Corp. 65 67 82 — —
Eli Lilly & Co. 134 106 83 — —
Gilead Sciences Inc. 31 58 39 — —
Johnson & Johnson 132 137 135 — —
Merck & Co. Inc. 89 89 123 — —
Pfizer Inc. 98 72 66 — —
Regeneron Pharmaceuticals Inc. 122 138 84 — —
Thermo Fisher Scientific Inc. 41 48 53 — —
Vertex Pharmaceuticals Inc. 106 103 79 — —
Average Payables Payment Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences 86 85 86 — —
Average Payables Payment Period, Industry
Health Care 61 63 63 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 9.03 = 40

2 Click competitor name to see calculations.


The analysis reveals a significant transition in the management of accounts payable between 2020 and 2023. An initial period of extreme volatility was followed by a normalization of payment cycles and a stabilization of operational efficiency.

Payables Turnover
A substantial increase in the turnover ratio is observed from 0.43 in 2020 to 8.67 in 2021, eventually peaking at 11.12 in 2022. This trajectory indicates a rapid acceleration in the frequency with which obligations to suppliers were settled. A slight moderation occurred in 2023, with the ratio declining to 9.03, suggesting a stabilization of procurement and payment activities.
Average Payables Payment Period
The payment period exhibited a drastic reduction from an exceptional 845 days in 2020 to 42 days in 2021. This shift represents a move from an anomalous payment cycle to a standard operational timeframe. The period reached a minimum of 33 days in 2022 before slightly increasing to 40 days in 2023. This trend demonstrates a consistent and disciplined approach to managing short-term liabilities over the last three reporting periods.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Cash Conversion Cycle

Moderna Inc., cash conversion cycle calculation, comparison to benchmarks

No. days

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data
Average inventory processing period 16 64 201 2,141 —
Average receivable collection period 49 27 66 2,539 —
Average payables payment period 40 33 42 845 —
Short-term Activity Ratio
Cash conversion cycle1 25 58 225 3,835 —
Benchmarks
Cash Conversion Cycle, Competitors2
AbbVie Inc. 82 85 70 — —
Amgen Inc. 441 273 228 — —
Bristol-Myers Squibb Co. 54 42 34 — —
Danaher Corp. 91 81 63 — —
Eli Lilly & Co. 261 219 197 — —
Gilead Sciences Inc. 132 104 111 — —
Johnson & Johnson 86 72 51 — —
Merck & Co. Inc. 118 93 105 — —
Pfizer Inc. 120 63 92 — —
Regeneron Pharmaceuticals Inc. 555 584 345 — —
Thermo Fisher Scientific Inc. 101 97 115 — —
Vertex Pharmaceuticals Inc. 166 112 119 — —
Cash Conversion Cycle, Sector
Pharmaceuticals, Biotechnology & Life Sciences 131 97 97 — —
Cash Conversion Cycle, Industry
Health Care 37 27 29 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 16 + 49 – 40 = 25

2 Click competitor name to see calculations.


A substantial contraction in the cash conversion cycle is observed between 2020 and 2023, indicating a significant acceleration in the efficiency of operating working capital. The cycle transitioned from an extreme outlier of 3,835 days in 2020 to a lean 25 days by the end of 2023, reflecting a fundamental shift in the company's operational velocity.

Average Inventory Processing Period
An aggressive downward trend is evident in inventory management. The processing period decreased from 2,141 days in 2020 to 16 days in 2023. This precipitous decline suggests a transition from early-stage stockpiling or low-volume production to a highly optimized, high-turnover distribution model.
Average Receivable Collection Period
The time required to collect payments from customers saw a massive reduction from 2,539 days in 2020 to 49 days in 2023. While a slight increase occurred between 2022 (27 days) and 2023 (49 days), the overall trajectory demonstrates a marked improvement in credit management and cash inflow efficiency compared to the initial period.
Average Payables Payment Period
The payment period for suppliers decreased from 845 days in 2020 to 40 days in 2023. The stabilization of this metric between 33 and 42 days from 2021 through 2023 indicates the establishment of a normalized procurement and payment cadence.
Cash Conversion Cycle Synthesis
The overarching trend reveals a move toward extreme liquidity efficiency. The drastic reductions in both inventory and receivable periods outweighed the reduction in the payables period, resulting in a net reduction of the cash conversion cycle. By 2023, the operating cycle had become highly streamlined, minimizing the time capital is tied up in the production and sales process.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?